Gregory Bluemling, PhD
Co-Founder,
Chief Executive & Scientific Officer
Bio
Dr. Bluemling is the Chief Executive and Scientific Officer of Blue Sky Pharmaceuticals and brings a successful background in translating basic research and innovative pharmaceutical technologies into clinical assets through academic-industry partnerships utilizing a robust and integrated development strategy. Dr. Bluemling was trained as a medicinal chemist at Emory University where he received his PhD in chemistry. With over two decades of drug discovery and preclinical development experience, including 10 years spent at the Emory Institute for Drug Development (EIDD), Dr. Bluemling has honed his expertise in infectious disease therapeutics through the whole spectrum from discovery and preclinical development to IND preparation and filing.
As a co-inventor of Molnupiravir, Dr. Bluemling has been instrumental in the development of this groundbreaking antiviral drug, which has significantly impacted the treatment of viral infections, including COVID-19. His contributions to the field extend beyond Molnupiravir, as he is listed as an inventor on more than 20 other patents. Currently, four of his compounds are in various stages of clinical development, underscoring his commitment to advancing innovative therapies.